Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Clinical trial NCT03822351 · COMPLETED
Trial details
- NCT number
- NCT03822351
- Sponsor
- MedImmune LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-19
- Primary completion
- 2023-07-18
- Enrollment
- 189
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.